CoChat

Structural and Functional Characterization of the Aryl Hydrocarbon Receptor Ligand Binding Domain by Homology Modeling and Mutational Analysis

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 10 of the 32 sources its claims cite were checked for support.

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that is activated by a structurally diverse array of synthetic and natural chemicals, including toxic halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Analysis of the molecular events occurring in the AhR ligand binding and activation processes requires structural information on the AhR Per-Arnt-Sim (PAS) B-containing ligand binding domain, for which no experimentally determined structure has been reported. With the availability of extensive structural information on homologous PAS-containing proteins, a reliable model of the mouse AhR PAS B domain was developed by comparative modeling techniques. The PAS domain structures of the functionally related hypoxia-inducible factor 2alpha (HIF-2alpha) and AhR nuclear translocator (ARNT) proteins, which exhibit the highest degree of sequence identity and similarity with AhR, were chosen to develop a two-template model. To confirm the features of the modeled domain, the effects of point mutations in selected residue positions on both TCDD binding to the AhR and TCDD-dependent transformation and DNA binding were analyzed. Mutagenesis and functional analysis results are consistent with the proposed model and confirm that the cavity modeled in the interior of the domain is indeed involved in ligand binding. Moreover, the physicochemical characteristics of some residues and of their mutants, along with the effects of mutagenesis on TCDD and DNA binding, also suggest some key features that are required for ligand binding and activation of mAhR at a molecular level, thus providing a framework for further studies.

Overview

CoChat Summary

## TL;DR

The paper builds and validates a homology model of the mouse AhR PAS B ligand-binding domain using HIF-2α and ARNT as templates, because no experimental AhR structure was available. Site-directed mutagenesis and binding assays support a buried cavity as the TCDD-binding site and identify residues that affect ligand binding and/or ligand-dependent DNA binding.

## Key findings

  • The best-supported model was the two-template HIF-2α/ARNT model: its PROSA z-score was -4.53 on average (best model -4.56), compared with -4.00 for the HIF-2α-only model; the multitemplate model was judged slightly better than the single-template one.
  • CASTp identified a buried cavity in the modeled AhR domain with a volume of 496 ų, and comparison of modeled and template structures suggested this cavity could accommodate ligand binding.
  • Mutagenesis showed that residues pointing outside the cavity generally did not affect TCDD binding, while cavity-facing or connector residues often did: H285A, I332P, M334E, and A375L completely eliminated both [³H]TCDD binding and TCDD-inducible DNA binding; C327A, M334A, E339A, A375V, and Q377A reduced DNA binding.
  • Quantitatively, Table 4 reports that TCDD-inducible DNA binding was 100% for wild-type AhR, 97% for T311A, 95% for K350A, 82% for C327A, 70% for M334A, 53% for E339A, 42% for A375V, and about 3% for A375L and M334E.

## Methods

  • Comparative/homology modeling was used to build mouse AhR PAS B LBD models from residues 230–421 using PSI-BLAST, structural alignment, and MODELLER; three template sets were tested, including a single-template HIF-2α model and two multitemplate models.
  • Structural pockets were analyzed with CASTp, and the I332P mutant and wild-type models were examined by 1 ns molecular dynamics simulations in GROMACS.
  • Site-directed mutagenesis tested selected residues (R282, H285, T311, C327, I332, M334, E339, K350, A375, Q377) in in vitro expressed mouse AhR; effects on [³H]TCDD binding and TCDD-dependent DNA binding were measured by hydroxyapatite binding assay and gel retardation assay.

## Limitations

  • The paper states that the models necessarily had some stereochemical restraint violations because of the medium-low degree of similarity between mAhR and the templates; this is an explicit limitation of the modeling.
  • The authors note that the ligand-binding assay is less sensitive than the gel retardation assay and that assay reagents can strip ligand from low-affinity AhRs; this is an evident experimental limitation in the text.
  • The paper also says that the observed effects of some mutations, especially E339A, may reflect protein-protein interaction effects and “deserve further in-depth analyses”; this is an explicit limitation of the current study.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1021/bi061460t

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Image 2
From the PDF
Image 3
From the PDF
Image 4
From the PDF
Image 5
From the PDF
Image 6
From the PDF
Image 7
From the PDF

Verification

Claims the paper makes

8 Valid · 0 Not valid · 6 Not checked · 66 Own results and interpretations

40 more claims

Create a free account to see all 80 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 69 references

Research works printed but not linked: 35

  1. Ma Q., 2001, Curr. Drug Metab. 2, 149−164.
  2. Denison M. S., 1998, Molecular Biology Approaches to Toxicology
  3. Denison M. S., 1998, Bull. Environ. Contam. Toxicol. 61, 557−568.
  4. Denison M. S., 2002, Chem.-Biol. Interact. 141, 3−24.
  5. Petrulis J. R., 2002, Chem.-Biol. Interact. 141, 25−40.
  6. Henry E. C., 2003, Mol. Pharmacol. 63, 392−400.
  7. Hord N. G., 1994, Mol. Pharmacol. 46, 618−624.
  8. Whitlock J. P., Jr., 1999, Annu. Rev. Pharmacol. Toxicol., 39
  9. Fukunaga B. N., 1995, J. Biol. Chem., 270
  10. Perdew G. H., 1996, Biochem. Mol. Biol. Int. 39, 589−593.
  11. Ema M., 1994, J. Biol. Chem., 269
  12. Poland A., 1994, Mol. Pharmacol. 46, 915−921.
  13. McGuire J., 2001, J. Biol. Chem., 276
  14. Gong W., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
  15. Crosson S., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
  16. Bonati L., 2002, Organohalogen Compd. 59, 429−432.
  17. Erbel P. J., 2003, Proc. Natl. Acad. Sci. U.S.A. 100
  18. Card P. B., 2005, J. Mol. Biol., 353
  19. Berman H. M., 2000, Nucleic Acids Res. 28, 235−242.
  20. Kelley L. A., 1996, Protein Eng. 9, 1063−1065.
  21. Getzoff E. D., 2003, Nat. Struct. Biol. 10, 663−668.
  22. Altschul S. F., 1997, Nucleic Acids Res. 25, 3389−3402.
  23. Fiser A., 2000, Protein Sci. 9, 1753−1773.
  24. MacKerell A. D., Jr., 1998, J. Phys. Chem. B, 102
  25. Thompson J. D., 1994, Nucleic Acids Res. 22, 4673−4680.
  26. Sippl M. J., 1993, Proteins 17, 355−362.
  27. Sanchez R., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
  28. Dundas J., 2006, Nucleic Acids Res. 34, W116−W118.
  29. Berendsen H. J. C., 1995, Comput. Phys. Commun., 91, 56
  30. Rushing S. R., 2002, Arch. Biochem. Biophys. 403, 189−201.
  31. Sali A., 1995, Proteins 23, 318−326.
  32. Liang J., 1998, Protein Sci. 7
  33. Harper P. A., 1992, Mol. Pharmacol. 42, 603−612.
  34. Bonati L., 1995, Part 2, J. Mol. Struct. (Theochem), 340, 95
  35. Meyer E. A., 2003, 42, 1210−1250.

Cited by

See all 160

Metadata

Authors
Pandini, A., Denison, M. S., Song, Y., Soshilov, A. A., & Bonati, L.
Affiliations
University of Milano-Bicocca (IT)
Corresponding author
Bonati, Laura
Venue
Biochemistry
Published
2006-12-23
Volume
46
Issue
3
Pages
696-708
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
OpenAlex
W2081410156
Cited by
160
References
68
Citations by year
2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 24 · 2020: 10 · 2019: 11 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 10
FWCI
6.34
Type
journal article
Language
en
Open access
Locations
  • Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Brunel University Research Archive (BURA) (Brunel University London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • National Institutes of Health (5p30es005707-15)
  • Division of Agriculture and Natural Resources, University of California
  • National Institute of Environmental Health Sciences (F32ES005707, ES 07685, R01ES007685, ES05707, P30-ES0-05707)
Topics
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
aryl hydrocarbon receptor, PAS-B domain, ligand-binding domain, TCDD, homology modeling, HIF-2α, ARNT, point mutations, ligand-binding cavity, DNA binding, transcription factor activation
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Amino Acid Sequence, Animals, Binding Sites, Humans, Ligands, Models, Molecular, Molecular Sequence Data, Transcription Factors, Mutagenesis, Site-Directed, Sequence Alignment, Protein Structure, Tertiary, Receptors, Aryl Hydrocarbon, Structural Homology, Protein, Mice, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.